Novartis’ $12B Avidity buy pays dividends with Phase 1/2 muscular dystrophy win

The RNA-based medicine is one of a handful of antibody-oligonucleotide conjugates that Novartis acquired last October when it took over neuromuscular-focused Avidity Biosciences.